StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Saturday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of NASDAQ:ADXS opened at $0.03 on Friday. The firm has a 50 day simple moving average of $0.04 and a 200 day simple moving average of $0.17. The company has a market cap of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.81. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.